Lumiliximab facts

Lumiliximab is a chimeric monoclonal antibody that targets CD23. It acts as an immunomodulator and, as of October 2009, it is being investigated in Phase I and II clinical trials for the treatment of chronic lymphocytic leukemia.

Read article at Wikipedia

Facts from the Community

From the BioVenturist base

Target/Biomolecule of Interest:

CD23

Indication or disease:

Disease	Phase of development
B-cell lymphoma	Phase III Clinical Trial
Chronic lymphocytic leukemia	Phase III Clinical Trial

View entire collection »

top ↑

We can tell you that Lumiliximab is a…

…Drug
…Medical Treatment

If you know more about Lumiliximab, you can add more facts here »

These people have edited this topic:

Metaweb Staff
tristan
- Member Since: Nov 30, 2006
- Contributions: 3,066,378 Facts

Edit this topic

Last edited Nov 29, 2008 See all topic history »

Lumiliximab elsewhere on the web

Wikipedia

Lumiliximab

Facts from the Community

From the BioVenturist base

Target/Biomolecule of Interest:

Indication or disease:

Technology involved:

Developed by:

Stage of development:

We can tell you that Lumiliximab is a…

These people have edited this topic:

tristan

Lumiliximab elsewhere on the web

What is Freebase?

Flag this Topic

Why do you want to flag this topic?

Lumiliximab

Facts from the Community

From the BioVenturist base

Target/Biomolecule of Interest:

Indication or disease:

Technology involved:

Developed by:

Stage of development:

We can tell you that Lumiliximab is a…

These people have edited this topic:

tristan

Related Topics

Lumiliximab elsewhere on the web

What is Freebase?

Flag this Topic

Why do you want to flag this topic?